Press Releases

Press Releases

January 27, 2020
Primary Endpoint of Non-Inferiority Achieved with Responder Rates* of 65.02% for PrabotulinumtoxinA and 62.56% for OnabotulinumtoxinA at Week 4 NEWPORT BEACH, Calif. , Jan. 27, 2020 (GLOBE NEWSWIRE) -- Evolus , Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach